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BACKGROUND: Although several markers have been
used for enrichment of cells with stem cell-like properties
in oral squamous cell carcinoma (OSCC), isolation of a
pure subpopulation is still a challenging task. Normal oral
and esophageal keratinocyte stem cells have been previ-
ously isolated using the low-affinity nerve growth factor
receptor p75NTR.
OBJECTIVE: To investigate the potential of p75NTR as a
marker for identification and isolation of oral cancer cells
with stem cell-like properties.
METHODS: Subpopulations of cells with high or low
expression of p75NTR were sorted from OSCC-derived
cells and compared for sphere/colony formation, in vivo
tumor formation ability, expression of stem cell-related
molecules, cell cycle distribution and drug resistance.
RESULTS: p75NTRHigh cells exhibited statistically signif-
icant higher stem cell properties than p75NTRLow cells in
all assays performed. Nevertheless, p75NTRLow subpop-
ulation did also exhibit some stem cell features, but to a
lesser extent. Propagation of p75NTRLow cells for several
passages in culture showed that the expression of
p75NTR could rise spontaneously. This finding was also
supported by the similar expression of p75NTR by the
xenografts generated by both subpopulations in NOD
\SCID IL2Rgnullmice.
CONCLUSION: p75NTR can be used for isolating a
subpopulation enriched for cells with stem cell-like prop-
erties in OSCC. De novo generation of p75NTRHigh cells
from p75NTRLow cells suggests either that there is
another subpopulation with stem cell features within the
p75NTRLow cells, or that the p75NTRLow cells can dedif-
ferentiate due to a contextually regulated equilibrium
between stem cell-like cells and transit-amplifying neo-
plastic progenitors.
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Introduction
The notion that tumor growth is driven by a subpopulation
with stem cell properties, referred to as cancer stem-like
cells (CSCs), or tumor-initiating cells (TIC), has attracted
much attention during the last decade (1). Research in acute
myeloid leukemia (AML) provided the ﬁrst persuasive proof
of the CSC theory (2, 3). Those pivotal ﬁndings have led to
the investigation of the existence of CSCs in many solid
tumors, and their presence has been shown in several solid
malignancies, such as breast (4), colon (5), brain (6),
prostate (7), lung (8), liver (9), and melanoma (10). In some
human cancers, a role for CSCs in tumor recurrence (11),
chemotherapy resistance (12), and metastasis (13) has been
suggested. Therefore, it has been theorized that identiﬁca-
tion of distinctive phenotypical characteristics of CSCs
would provide a promising target for a better, more targeted,
and efﬁcient form of cancer treatment. Analogical to normal
adult stem cells, CSCs are deﬁned as the cells with (i) self-
renewal ability/tumor initiation ability and (ii) the ability to
generate all more differentiated phenotypes forming the
bulk cells of a tumor (1). The experimental functional CSC
assays are thus aimed to investigate those distinctive
features. Xenotransplantation into animal models, also
known as in vivo tumor formation assay, is the most
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accepted CSC/TIC assay, despite of its inadequacies, and it
is considered the benchmark for other assays (1). Sphere
formation assay is based on the ability of stem cells to
self-renew and grow independent of anchorage, and it is
considered the in vitro surrogate for the in vivo tumor
formation assay (14).
Although the CSC model has been proven in some
human cancers, the available evidence in others cannot
refute that the difference in the tumorigenicity of cancer
cells and phenotypic heterogeneity can also arise as a result
of the genetic instability, and expansion of mutated clones
(15, 16). Moreover, it has been recently shown in metastatic
colon cancer that the two models can coexist, by observing
that chromosomal instability takes place preferentially in
cells exhibiting CSC behavior (17). The plasticity of tumor
cells might also play a role, and a switching of CSC between
different phenotypes was reported in oral squamous cell
carcinoma (OSCC) (18) and breast cancer (19).
In OSCC, the most common type of head and neck cancers,
several subpopulations have been reported to be enriched for
CSCs. Among these, CD44High (20), ALDH1High (21), and
the side population (22) have been suggested. However, a
pure CSC subpopulation is yet to be identiﬁed, and recent
evidence suggests that the cancer stemness is a rather
dynamically regulated phenotype than a distinct entity. The
low-afﬁnity nerve growth factor receptor p75NTR was
described as a putative marker of normal oral (23) and
esophageal (24) keratinocyte stem cells. Although structur-
ally belonging to the tumor necrosis factor receptor super-
family (25), many of the biological functions of p75NTR
differ from other members of this family, and a role in
promoting cell survival has been suggested in normal human
oral mucosa (NHOM) (23) and nerves (26). Furthermore,
possible role of thismolecule in carcinogenesiswas suggested
in laryngeal, prostate, and breast cancers (27–29). It has also
been suggested as a marker of CSCs in malignant melanoma
(30), esophageal carcinoma (31), and it was found to be a
determinant of poor prognosis in OSCC (32, 33). Neverthe-
less, recent data from 3D stepwise models of OSCC indicated
a loss of CD44 and p75NTR hierarchical coordination with
OSCC progression (34), bringing more controversy into the
issue of phonotypical markers, such as p75NTR or CD44, as
good markers for stem cell identiﬁcation and isolation.
In AML, markers of normal stem cells of the tissue of
origin have been successfully used to isolate CSCs (2);
therefore, we hypothesized that p75NTR, as a marker of
normal oral keratinocyte stem cells, comprises a putative
CSC marker in OSCC.
Materials and methods
Cell culture
Oral squamous cell carcinoma-derived cells of the cell lines,
known as CalH3 (p53 wild) and 5PT (p53 mutated) (35),
were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 25% nutrient mixture F-12
Ham, 50 lg/ml L ascorbic acid, 0.4 lg/ml hydrocortisone,
10 ng/ml epidermal growth factor (all from Sigma-Aldrich,
Saint Louis, MO, USA), 10% fetal bovine serum (FBS), and
5 lg/ml insulin (both from Life Technologies, Carlsbad,
CA, USA), also known as FAD medium (36), under
standard culture conditions. Cells were used at 16–24
passages.
Fluorescent-activated cell sorting (FACS)
Cells were detached at 70–80% conﬂuency using 19 trypsin-
EDTA (Sigma-Aldrich), counted and resuspended in phos-
phate-buffered saline (PBS) containing FBS and HEPES
(Life technologies) as 1% each. Afterward, cells were
incubated with mouse monoclonal anti-p75NTR antibody
(clone ME20.4, 1:250; Sigma) for 10 min on ice. Negative
control mouse IgG1 (1:250; Dako, Golstrup, Denmark) was
used as an isotype control. After a washing step, cells were
incubated with Alexa Fluor 488 F(ab1)2 fragment of goat
anti-mouse H+L (1:250; Life technologies) for another
10 min on ice and protected from light. All FACS procedures
were performed with BD FACSAriaTMIIu (BD Biosciences,
Franklin Lakes, NJ, USA), using 525/50 BP ﬁlter. Cells with
considerably small size or smooth surface (apoptotic), as well
as doublets, were gated out according to forward- and side-
scattered light, and further analysis was performed only on the
main population of cells. The highest and lowest 5% of the
cellswere sorted and collected in FADmedium.All sortswere
followed by post-sort FACS checking. Independent sorts
were carried out at different passages.
Colony formation assay
Cells sorted according to expression of p75NTR were
seeded in 6-well plates as 500 cells in 3 ml of FAD
medium/well and allowed to grow under standard culture
conditions for 7–15 days. After examining microscopically,
wells were washed with PBS, and 2 ml of cold 4%
paraformaldehyde (Sigma-Aldrich) was added to ﬁx the
colonies. The wells were washed again after 10 min and
stained with 0.5% crystal violet (Sigma). The minimum
number of cells in a colony was set to 50 cells, and
calibration to the minimum size of a colony was made
before counting the colonies macroscopically. Independent
experiments were performed for three different passages.
Sphere formation assay
To prepare non-adherent culture plates, 1% solution of poly
2-hydroxyethyl methacrylate (pHEMA; Sigma) in ethanol
was used to coat 96-well plates. Five hundred p75NTRHigh
or p75NTRLow CalH3 cells were resuspended in a mixture
of 475 ml of FAD medium and 25 ll of Matrigel (BD
Bioscience) and loaded into each well. Cells were allowed
to grow for 2 weeks under standard culture conditions, and
the number of spheres was counted under an inverted
microscope. Independent experiments were performed at
three different passages.
Cell cycle analysis
Unsorted, p75NTRHigh and p75NTRLow CalH3 cells were
ﬁxed using chilled 70% ethanol for 1 h on ice, washed in
chilled PBS, and centrifuged at 300 g for 5 min at 4°C
degrees. Cells were incubated with propidium iodide (PI)
solution for half an hour at 37°C in the dark. For every one
million cells, PI solution consisted of 50 ll of PI (1000 lg/
ml; Life technologies), 125 ll of RNAse (1 mg/ml; Sigma),
380 ll of Na citrate (100 nM), and 445 ll of 19 PBS. Cells
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were then washed and centrifuged again in PBS and
analyzed in Accuri6 cytometer (BD Biosciences). For each
sample, at least 30 000 events were recorded and analyzed
in Flowjo version 10 (Tree star Inc., Ashland, OR, USA)
using Dean–Jett–Fox model. Three independent experi-
ments performed at different passages were performed.
Drug resistance assay
Sorted cells were seeded in 96-well plate at density of
5000 cells/well and allowed to grow in FAD medium. After
48 h, the medium was replaced by 100-ll fresh FAD
medium containing 5-ﬂuorouracil (Sigma) at concentration
of 0, 2, 4, 8, 16, or 32 lg/ll in quadruplicates and kept
under standard culture conditions for another 48 h. After-
ward, 10 ll of WST-1 (Roche Applied Sciences, Penzberg,
Germany) was added to each well, and the light absorbance
was read 2–3 h later at 440 nM wavelength in FLUOstar
Omega plate reader (BMG LABTECH, Ortenberg, Ger-
many). The difference in the absorbance between the two
phenotypes at each of the drug concentration used was
investigated as a paired sample. Four independent experi-
ments performed at different passages were carried out.
In vivo tumor formation assay
The animal experiments were approved by the Norwegian
Animal Research Authority. The animals used were 20
NOD\SCID IL2Rgnull mice (n = 10 in each group) (Jackson
Laboratories, Bar Harbour, ME, USA). Five thousand
p75NTRHigh or p75NTRLow CalH3 cells were suspended
in 25 ll of Matrigel and injected into the tongues of the
mice under anesthesia with isoﬂurane (Isoba VetTM)
(Schering Plough, Kenilworth, NJ, USA) (3% induction
and 1% maintenance). The mice were examined for tumor
formation every week, starting 2 weeks from the day of
injection and measured bidirectionally using a caliber, under
gas anesthesia. Tumor size was calculated using the
following formula: volume = (width)2 * length/2. Animals
were sacriﬁced after 53 days, and tongues were collected, in
addition to the locoregional lymph nodes when visible, ﬁxed
in formalin and embedded in parafﬁn. Tumor formation was
conﬁrmed using H&E stained sections. Means of the tumor
sizes as recorded every week were compared between the
two animal groups in a pairwise manner.
Immunohistochemistry (IHC)
Formalin-ﬁxed parafﬁn-embedded sampleswere cut into 3- to
4-lm sections as duplicates on each slide. Sections were then
deparafﬁnized and rehydrated by immersion in xylene and
diminishing concentrations of alcohol. Retrieval of the
epitopewas performed by heating the sections in amicrowave
oven in a pH 6.0 target retrieval buffer (Dako). For p75NTR
staining, sections were incubated with 19 trypsin for 10 min
at 42°C. Endogenous enzyme activity and unspeciﬁc binding
were blocked using peroxidase block and 10% normal goat
serum, respectively (both from Dako). Sections were then
incubated over night at 4°C with one of the following
monoclonal mouse anti-human primary antibodies: anti-Ki-
67 (1:1500; Dako), anti-p75NTR (1:1000; Sigma), and
NovcastraTM anti-involucrin (1:1000; Leica Biosystems,
Wetzlar, Germany). Envision+ anti-mouse (Dako) was
used to detect the site of reaction according to the
manufacturer’s instructions. And the reaction was visualized
using 3,30-diaminobenzidine tetrahydrochloride (DAB).
Incubation with primary antibody was omitted for negative
control sections, and NHOM samples have been used as a
positive controls (37). Sections were then counterstained with
hematoxylin (Dako), dehydrated, and cover-slipped.
Evaluation of IHC
Sections subjected to IHC were evaluated by the principal
investigator (TO) after calibration with another investigator
(DS) using a light microscope equipped with 963 objective
(Leica) and Zeiss digital camera operated by Zen 2011
software (Carl Zeiss AG, Jena, Germany). The labels of the
slides were covered, and four random ﬁelds were evaluated.
Frequency of p75NTR-positive cells was evaluated semi-
quantitatively and scored into four levels (0: <5%, 1:
5–25%, 2: 26–50%, and 3: >50%). Frequency of Ki-67-
positive cells was quantiﬁed as percentage of the total
number of cells/ﬁeld, and the mean percentage of each
section was calculated. The difference between the means of
IHC scores, for both p75NTR and Ki-67, was investigated.
For evaluation of involucrin staining, slides were scanned
using Scanscope XT (Aperio, Vista, CA, USA) using 209
objective, and color deconvolution algorithm, version 9.1,
was employed to measure the total staining area and
intensity of the staining, using default parameters of the
algorithm (37). From the algorithm output, mean staining
score (1.0*(%weak) + 2.0*(%medium) + 3.0*(%strong)
was compared between samples from the two animal
groups. Additionally, difference in the mean of the total
optical density was investigated.
Quantitative reverse transcriptase PCR
Total RNA was extracted from both p75NTRHigh and
p75NTRLowCaLH3 cells using RNeasy ﬁbrous tissue mini
kit protocol (Qiagen, Venlo, Limburg, the Netherlands).
Following manufacturer’s instructions, 300 ng of total RNA
was converted to cDNA using High-Capacity cDNA Archive
Kit system (Life technologies). All qRT-PCR ampliﬁcations
were performed on ABI Prism Sequence Detector 7900 HT
(Life technologies) as described previously (38). qRT-PCR
was performed to examine the expression levels of the
following genes (TaqMan assays): NGFR
(Hs00609947_m1), PDPN (Hs00366766_m1), CD44
(Hs01075861_m1), POU5F1 (Hs 00999632_g1), BMI1
(Hs00180411_m1), VIM (HS00185584_m1), KRT10
(HS00166289_m1), and IVL (HS00902520_m1), encoding
p75NTR, podoplanin, CD44, Oct4, BMI1, vimentin, cyto-
keratin 10, respectively. Comparative 2-DD Ct method was
used to quantify the relative mRNA expression, and GAPDH
(Hs99999905_m1) was used as endogenous control.
Statistical analysis
Analysis of the qRT-PCR data was performed in GraphPad
Prism 6 (GraphPad, La Jolla, CA, USA), while all other
statistical procedures were conducted in Statistical Package
for Social Sciences (SPSS), version 19 (IBM, Armonk, NY,
USA). Normality of the distributions of continuous vari-
ables was explored using Shapiro–Wilk test. Differences in
the means were investigated either with Student’s t-test or
with Mann–Whitney U-test, as the parametric and the
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non-parametric tests of choice, respectively. Pairwise com-
parison of the tumor growth between the two xenograft
groups, or the light absorbance in the drug resistance assay,
was investigated by related samples Wilcoxon signed rank
test. In all statistical procedures, the level of signiﬁcance
was set to 0.05.
Results
p75NTRHigh cells showed higher ability than p75NTRLow
cells to form colonies and spheres in vitro
The expression of p75NTR was found to have a gradient
pattern, and no well-separated positive and negative subpop-
ulations were found by FACS analysis (Fig 1A, B). There-
fore, the highest and lowest 5% p75NTR-expressing cells
were deﬁned as p75NTRHigh and p75NTRLow cells (Fig. 1C).
The FACS procedure (Fig. 1A–C) yielded constantly highly
pure sorted subpopulations of p75NTRHigh (98.2%  0.87 in
CaLH3 and 98.6%  0.24 for 5PT) and p75NTRLow
(98.8%  0.84 in CaLH3 and 98.2  0.59 for 5PT) cells,
as conﬁrmed by repeating the FACS analysis for part of the
sample immediately after the sorting session (Fig. 1D,
Figure S1B) and by subsequent qRT-PCR of the sorted cells
(Fig. 2A). Both subpopulations of cells sorted for high and
low expression of p75NTR were found to be able to form
spheres, but the number of spheres formed by p75NTRHigh
cells was found to be signiﬁcantly higher (P = 0.000 for both
cell lines); the number of spheres formed by p75NTRHigh cells
comprised 4.14%  1.28 for CaLH3 and 12.8%  3.97 for
5PT of the total number of cells seeded, compared to only
1.7%  0.58 and 3.8%  2.92% for p75NTRLow cells in
CaLH3 and 5PT, respectively (Fig. 2C,D). Colony formation
assay revealed that signiﬁcantly higher percentage
(44%  2.58 for CaLH3 and 16.4  13.03 for 5PT) of
p75NTRHigh cells formed colonies when compared to
p75NTRLow cells (25.3%  3.4, P-value = 0.000 for
CaLH3 and 13.02  2.4, P = 0.038 for 5PT) (Fig. 2E, F).
p75NTRHigh cells were more tumorigenic than p75NTRLow
cells in vivo
The incidence of tumor formation was found to be higher in
mice injected with p75NTRHigh than in mice injected with
p75NTRLow CaLH3 cells (90% and 70%, respectively). The
most striking difference in the incidence of tumor formation
was observed at early stages (70% for p75NTRHigh com-
pared to 30% for p75NTRLow at the ﬁrst reading), which
indicated a longer lag phase for tumor formation of
p75NTRLow cells (Fig. 3A). Although tumor sizes were
found to be heterogeneous within each of the two groups,
pairwise comparison of the mean tumor size between the
two animal groups at each of the time points showed that
tumors generated by p75NTRHigh cells were growing
signiﬁcantly bigger than the tumors generated by
p75NTRLow cells (P-value = 0.043, Wilcoxon signed rank
test) (Fig. 3B).
p75NTRHigh cells expressed higher levels of stem cell-
related markers than p75NTRLow cells
qRT-PCR revealed that compared to p75NTRLow cells, the
p75NTRHigh CaLH3 cells had signiﬁcantly higher expres-
sion levels of surface markers previously reported as CSC
markers, namely CD44 and D2-40. Additionally, expression
A B C D
E F G H
Figure 1 Fluorescent-activated cell sorting (FACS) of oral squamous cell carcinoma (OSCC)-derived cells (CaLH3 cell line) according to p75NTR
expression. Cells immunostained with isotype control (A) were used to set the positive signal threshold for cells immunostained with anti-P75NTR antibody
(B). The highest and lowest 5% of the cells were sorted accordingly (C), followed by post-sorting check (D). p75NTRHigh cells immunostained with isotype
control after propagation in culture for 7 days (E), and the same gate as in A was found applicable. p75NTRHigh (F) and p75NTRLow (G) cells immunostained
with anti-p75NTR antibody after propagation for 7 days in culture, same gate as in A and E. Bar chart illustrating the change in the percentage of p75NTR
+ve and ve CaLH3 cells from day 1 to day 7 (H). Error bars represent standard deviation.
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of the more universal/embryonal stem cell marker Oct-4A
was found to be signiﬁcantly higher in p75NTRHigh CaLH3
cells, while the epithelial-to-mesenchymal transition (EMT)
marker vimentin and stem cell and EMT-/CSC-related
marker ALDH1 were found expressed at a lower level by
p75NTRHigh CaLH3 cells. Higher expression of the differ-
entiation markers (CK-13 and involucrin) by p75NTRLow
CaLH3 cells was also found to be signiﬁcantly different
from that of p75NTRHigh cells (Fig. 2A,B). p75NTRHigh
5PT cells showed also lower expression of the differenti-
ation markers (CK10) and EMT marker vimentin, but
signiﬁcantly higher expression of the CSC stem cell marker
ALDH1 only (Figure S1A).
Higher percent of p75NTRHigh cells were at the G2 phase
and displayed signiﬁcantly higher drug resistance than
p75NTRLow cells
Higher proportion of p75NTRHigh CaLH3 cells (32.07%
 9.2) were found to be at G2 phase compared to
p75NTRLow cells (8.91%  3.34) and the unsorted cell
population (22.15%  9.02) (Fig. 4A–C). The drug resis-






Figure 2 Comparison of the means of the expression levels, in a logarithmic scale, of stem cell- and epithelial-to-mesenchymal transition (EMT)-related
markers (A), and differentiation markers (B) in p75NTRHigh and p75NTRLow CalH3 cells, as yielded by qRT-PCR. Difference in sphere (C, D) and colony
(E, F) formation abilities between p75NTRHigh and p75NTRLow CaLH3 and 5PT cells. Error bars represent standard deviations.
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more resistant to5-ﬂuorouracil than p75NTRLow cells
(Fig. 4D).
Xenografts formed by both p75NTRHigh and p75NTRLow
cells contained a subpopulation of P75NTR+ cells
Tumor xenografts formed by both p75NTRHigh and
p75NTRLow CaLH3 cells showed a typical OSCC tumor
morphology, well differentiated, with keratin pearl forma-
tion and invasion in the surrounding tongue musculature
(Fig. 5A, B). No difference between the xenografts gener-
ated by the two different subpopulations of cells was
observed for the frequency of p75NTR-, Ki-67-, or invo-
lucrin-positive cells (Table 1, Fig. 5C–H). Of interest, a
stronger intensity of involucrin staining, evident by higher
staining score and total optical density (P-value = 0.008,
0.005, respectively), was observed in p75NTRHigh xeno-
grafts (Table 1).
p75NTRHigh cells could arise de novo from the p75NTRLow
cells
To investigate the dynamic of p75NTRHigh and p75NTRLow
subpopulations overtime, sorted subpopulations were fur-
ther propagated in vitro for a week, and FACS analysis was
performed as done before. The cell population arising from
the p75NTRHigh cells was found to contain only
41.6%  14.45 and 88.15%  1.7 p75NTR-positive cells
in CaLH3 and 5PT, respectively, as compared to the
concomitant isotype controls, indicating their ability to
regenerate both p75NTRLow and p75NTRHigh phenotypes
A
B
Figure 3 Comparison of the tumor formation incidence and tumor sizes
between animals injected with 5000 p75NTRHigh or p75NTRLow CaLH3




Figure 4 Cell cycle distribution of unsorted oral squamous cell carcinoma (OSCC)-derived cells (CaLH3 cell line) (A), p75NTRHigh (B), and p75NTRLow
(C) cells using Dean–Jett–Fox model. Comparison of the mean light absorbance between p75NTRHigh and p75NTRLow cells in CaLH3 and 5PT cell lines,
after 48-hour exposure to 5-ﬂuorouracil, and 2- to 3-hour incubation with WST-1(D). Error bars represent standard error of the mean.
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of OSCC cells. Interestingly, a subpopulation of p75NTR-
positive cells (9.4%  1.37 in CaLH3 and 4.1%  0.28 in
5PT) was also found in the cells arose from the parallel
p75NTRLow cells (Fig. 1E–H, Figure S1B), indicating as
well their ability to regenerate both p75NTRLow and
p75NTRHigh phenotypes of OSCC cells.
Discussion
The results of this study showed that the p75NTRHigh OSCC
cells are enriched in cells with stem cell-/tumor-initiating
abilities. It is known that monolayer culture conditions alter
the normal pattern of differentiation and proliferation of
cells and are not as accurate in restoring the original
phenotype as the 3D cultures for example (34), but despite
of this, cells with clonogenic properties and expression
patterns similar to those of TICs in vivo were shown to
persist in malignant cell lines and show similar cell cycle
characteristics and apoptotic resistance with the in vivo ones
(39). Thus, in addition to in vitro assays using OSCC-
derived cell lines, we have performed in vivo tumorigenic





Figure 5 Histological sections of tumor xenografts generated by p75NTRHigh (left) and p75NTRLow (right) cells. Sections stained with hematoxylin and
eosin (A, B), immunostained (brown color) for p75NTR (C, D), Ki-67 (E, F), and Involucrin (G, H). Immunohistochemically stained sections were
counterstained with hematoxylin.
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(5000 cells/injection). Compared to p75NTRLow cells, this
subpopulation was found to have higher tumor formation
incidence, with shorter lag phase and faster growth rate
when transplanted at the same low injection number into
immune-deﬁcient mice. In vitro assays revealed that
p75NTRHigh cell subpopulation had more sphere/colony
formation and drug resistance abilities. Cell cycle analysis
showed a high percentage of p75NTRHigh cells at the G2
phase, a phenomena that was previously showed to be a
characteristic of normal and malignant epithelial stem cells
(40). These results are also in line with the ones of Urdiales
et al. (41), which found on rat adrenal gland PC12 cells that
p75NTR was expressed mainly in late G1, S, and G2 phases
and that signaling in this phases would promote more
survival. The p75NTRHigh cell subpopulation was also more
resistant to drug treatments in both OSCC cell lines tested
here, corroborating the suggestion of Urdiales et al. that
signaling in this cell cycle phase is relevant more for
survival then for differentiation. Moreover, expression of
several stem cell markers was found to be higher in this
subpopulation. This is in line with previous studies from
normal tissues, showing that sorting for p75NTR alone is
sufﬁcient to enrich for cells with stem cell-like properties
both in oral mucosa (23, 42) and esophagus (24), as well as
in esophageal cancer (43). Of interest, expression of EMT–
CSC marker ALDH1(18) and the EMT-related marker
vimentin was lower in the p75NTRHigh, suggesting that
p75NTR selects preferentially the epithelial phenotype of
the CSC in oral carcinomas.
Nevertheless, p75NTRLow subpopulation exhibited also,
although to a lesser extent, some stem cell abilities. The
stem cell behavior found in the p75NTRLow subpopulation
could be thought of as a technical failure of a pure sorting,
as a result of a dedifferentiation of the p75NTRLow cells, or
as a manifestation of another subpopulation with stem cell
features within the p75NTRLow cells. Our post-sorting,
systematically performed for all of our experiments, indi-
cated the ﬁrst alternative as less likely to be the cause of the
stem cell behavior of the p75NTRLow subpopulation. We
are therefore more inclined to consider the other alternatives
more likely to be the cause of our observations. Using the
same antibody for both FACS analysis and IHC, we found
that p75NTR-positive (+ve) cells could arise from the more
differentiated p75NTR negative (ve) cells, both in vivo
and in vitro. De novo generation of p75NTRHigh cells from
p75NTRLow cells might be the result of a contextually
regulated equilibrium between stem cell-like cells and
transit-amplifying neoplastic progenitors and thus could be
interpreted as a consequence of a dedifferentiation occurring
in the progenitor cells. It has been previously argued that the
hierarchy of cancer cell population suggested by the CSC
model must coexist with other phenomena that can lead to
tumor heterogeneity, including clonal expansion and revers-
ible changes in cancer cell properties (15). For example,
taking breast cancer as a model, it has been recently shown
that the proportions of different phenotypes vary over time
with a tendency to return back to equilibrium. This was
found to take place stochastically, and CSCs were found to
arise from non-stem-like cells (19). In the current study, the
appearance of p75NTR-ve cells from p75NTR+ve cells
could easily be explained by the asymmetrical division of
CSC, but the emergence of p75NTR+ve progeny from
p75NTR-ve cells is more difﬁcult to explain, and the
occurrence of a dedifferentiation process, similar to the one
occurring in the above-mentioned breast cancer study,
cannot be excluded. This process might occur in OSCC,
similar to breast cancer, as a systematic event during cancer
progression that drives the population toward initial equi-
librium. Accordingly, the stem cell characteristics detected
later in culture or after in vivo injection of the more
differentiated p75NTRLow cells might be attributed to the
p75NTRHigh cells generated from them by dedifferentiation.
The differences in the stem cell characteristics between the
two subpopulations might be then explained as a time-
dependent phenomenon, as dedifferentiation of p75NTRLow
in p75NTRHigh cells might take some time. Allowing more
time for the p75NTRLow subpopulation might perhaps lead,
at some later time point, to the initial equilibrium of that
particular OSCC population. The fact that p75NTRLow cells
were able to form tumors in immunodeﬁcient mice, but with
a longer lag phase might be also taken as a further
corroboration for this hypothesis. In the same line point,
also the ﬁndings from the immunohistochemical analysis of
the xenografts showing that, while fully formed, the tumors
initiated by the p75NTRLow cells were not different from the
tumors initiated by the p75NTRhigh cells (in terms of
p75NTR expression and the frequency of proliferating
cells).
De novo generation of p75NTRHigh cells from
p75NTRLow cells might also be a consequence of the
presence of another subpopulation with stem cell features
within the p75NTRLow cells. The switching ability of
multiple, coexistent subpopulations of OSCC cells with
stem cell properties can, again, not be excluded. There are
previous studies that showed that within OSCC, multiple
CSC subpopulations with distinct phenotype coexist, each
of them predominating at one time point and being
responsible for tumor formation and self-renewal, but able
to switch their phenotype between them in certain
conditions. In this line, it was previously shown in OSCC
that CSCs can switch between epithelial/proliferative and
EMT phenotypes. This characteristic was found to be
restricted to ALDH1+ cells (18); therefore, exploring the
relationship between p75NTR+ and ALDH1+ subpopula-
tions in OSCC might provide more insight into the extent to
Table 1 Comparison of the immunohistochemistry (IHC) scores of
p75NTR and Ki-67, and the total optical density and the staining scores
of involucrin between xenografts generated by p75NTRHigh (N = 9) and
p75NTRLow (N = 7) CaLH3 cells
Parameter
quantiﬁed
after IHC Xenograft type Mean Median SD P-value
p75NTR score P75NTRHigh 1.167 1.00 0.217 1.000
P75NTRLow 1.179 1.00 0.238
Ki-67 score P75NTRHigh 52.207 53.605 11.482 0.210
P75NTRLow 59.603 54.512 11.450
Involucrin score P75NTRHigh 56.712 53.408 8.227 0.008
P75NTRLow 77.243 72.831 17.302
Involucrin total
optical density
P75NTRHigh 3.797 3.542 0.699 0.005
P75NTRLow 6.124 5.609 2.142
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which the CSC model is applicable to OSCC. Nevertheless,
although allowing longer time for tumor formation, the
p75NTRLow cells could not initiate tumors with the same
incidence as p75NTRHigh cells, suggesting that, although
transitory, there is an initial difference in the stem cell
properties between these two populations sorted for their
differential expression of p75NTR. This was also showed
by the prominent difference in the expression levels of
several relevant CSC genes using RNA extracted from the
two subpopulations immediately after FACS sorting, indi-
cating that p75NTR can be used for isolating a subpopu-
lation of OSCC cells enriched for cells with stem cell-like
properties in OSCC at a certain time point.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1 Comparison of the means of the expression
levels, in a logarithmic scale, of stem cell- and EMT-related
markers, and differentiation markers in p75NTRHigh and
p75NTRLow 5PT cells, as yielded by qRT-PCR (A). Bar
chart illustrating the change in the percentage of p75NTR
+ve 5PT cells from day 1 to day 7 (B), error bars represent
standard deviation.
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